利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

69 条记录 (耗时 0.011 秒)

    TOPICAL COMPOSITIONS COMPRISING AN OPIOID ANALGESIC AND AN NMDA ANTAGONIST
    5.
    发明授权
    TOPICAL COMPOSITIONS COMPRISING AN OPIOID ANALGESIC AND AN NMDA ANTAGONIST 有权
    局部组合物含有阿片类镇痛药AND A NMDA拮抗剂

    公开(公告)号：EP1102589B1

    公开(公告)日：2006-11-02

    申请号：EP99934071.4

    申请日：1999-07-15

    申请人： MEMORIAL SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH

    发明人： KOLESNIKOV, Yuri ,  PASTERNAK, Gavril, W.

    IPC分类号： A61K31/485 ,  A61K31/4468 ,  A61K31/4535 ,  A61K38/33 ,  A61P23/00 ,  A61L29/00 ,  A61P29/00 ,  A61K31/138 ,  A61K31/13 ,  A61K31/445

    CPC分类号： A61K38/33 ,  A61K45/06

    摘要： A topical opioid paradigm was developed to determine analgesic peripheral effects of morphine. Topical morphine as well as peptides such as [D-Ala2,MePhe4,Gly(ol)5]enkephalin (DAMGO) produced a potent, dose-dependent analgesia using the radiant heat tailflick assay. The topical drugs potentiated systemic agents, similar to the previously established synergy between peripheral and central sites of action. Local tolerance was rapidly produced by repeated daily topical exposure to morphine. Topical morphine tolerance was effectively blocked by the N-Methyl-D-Aspartate (NMDA) receptors antagonist MK801 and ketamine given either systemically or topically. NMDA receptor antagonists reversed pre-existing morphine tolerance. The activity of topical NMDA antagonists to block local morphine tolerance suggests that peripheral NMDA receptors mediate topical morphine tolerance. Morphine was cross tolerant to [D-Ala2,MePhe4,Gly(ol)5]enkephalin (DAMGO), but not to morphine-6 beta -glucuronide, implying different mechanisms of action. These observations have great importance in the design and use of opioids clinically. Topical pharmaceutical compositions comprising an analgesic that functions through an opiate receptor and an NMDA receptor antagonist for producing analgesia without inducing tolerance are described.

    METHODS FOR INDUCING SUSTAINED IMMUNE RESPONSE
    6.
    发明公开
    METHODS FOR INDUCING SUSTAINED IMMUNE RESPONSE 有权
    方法释放一个持续的免疫反应

    公开(公告)号：EP1401474A4

    公开(公告)日：2005-05-11

    申请号：EP02746503

    申请日：2002-05-16

    申请人： PLOTNIKOFF NICHOLAS P

    发明人： PLOTNIKOFF NICHOLAS P

    IPC分类号： A61K38/00 ,  A61K38/12 ,  A61K38/33 ,  A61P35/00 ,  A61P37/00

    CPC分类号： A61K38/1709 ,  A61K38/00 ,  A61K38/33 ,  A61K45/06

    摘要： A method for promoting a sustained increased level of T-cell production in immunocompromised subjects in which method enkephalin peptides are administered according to an intermittent dose schedule. In particular, the method involves treatment of immunocompromised patients which includes the administration of enkephalin, either alone or in conjunction with other therapies, in an initial dosage regimen, with periodic booster dosages of enkephalin as necessary to maintain sustained immune system response.

    METHODS FOR DETERMINING WHETHER A PATIENT IS LIKELY TO BENEFIT FROM TREATMENT WITH A THERAPEUTIC FORMULATION
    10.
    发明公开
    METHODS FOR DETERMINING WHETHER A PATIENT IS LIKELY TO BENEFIT FROM TREATMENT WITH A THERAPEUTIC FORMULATION 审中-公开

    公开(公告)号：EP3417292A1

    公开(公告)日：2018-12-26

    申请号：EP17791441.3

    申请日：2017-10-10

    申请人： Iconic Intellectual Property Limited

    发明人： MCINTOSH, Deirdre Patricia ,  HAQ, Syed Ebadat

    IPC分类号： G01N33/564 ,  A61K38/22 ,  G01N33/68 ,  A61K38/33

    摘要： The present invention relates to a method for determining whether a patient is likely to benefit from treatment with a therapeutic formulation, the method comprising the steps of: (a) determining the concentration of corticotropin releasing hormone (CRH) in a sample from a patient prior to administration of the therapeutic formulation; (b) determining the concentration of CRH in a sample from a patient subsequent to administration of the therapeutic formulation; and (c) comparing the concentration of CRH pre-administration with the concentration of CRH subsequent to administration; wherein an increase in patient CRH concentration subsequent to administration indicates that the patient is likely to benefit from treatment with the therapeutic formulation and wherein no increase or a decrease in patient CRH concentration subsequent to administration indicates that the patient is unlikely to benefit from treatment with the therapeutic formulation. The patient may have multiple sclerosis or systemic sclerosis. The therapeutic formulation may be derived from an ungulate such as a goat and may contain CRH, CRH-binding protein, pro-opiomelanocortin (POMC) and alpha-2 macroglobulin. Also provided are methods of treating a patient with a disorder such as multiple sclerosis or systemic sclerosis.